Status:
COMPLETED
Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma
Lead Sponsor:
Allergopharma GmbH & Co. KG
Conditions:
Respiratory Hypersensitivity
Eligibility:
All Genders
6-40 years
Phase:
PHASE3
Brief Summary
The trial is performed to assess efficacy and safety of the Allergopharma house dust mite allergoid in bronchial asthma.
Detailed Description
The rationale for the present study was to demonstrate clinical efficacy and tolerability compared to placebo in a phase III clinical study of pivotal character with a representative number of patient...
Eligibility Criteria
Inclusion
- Bronchial asthma
- Requirements for inhaled corticosteroid
- Positive skin prick test to house dust mite
- Positive radioallergosorbent test (RAST) to house dust mite
- Positive provocation test result to house dust mite
Exclusion
- Serious chronic diseases
- Other perennial allergies
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00263640
Start Date
May 1 2005
End Date
August 1 2012
Last Update
January 15 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Allergopharma GmbH & Co. KG
Reinbek, Germany, 21465